Clinical Trial Update: A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) [Phase 2]

View source ↗

Summary

This update describes a Phase 2 study of tarlatamab in relapsed/refractory small cell lung cancer; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Tarlatamab

Snippet

Sponsor: Amgen | Conditions: Relapsed/Refractory Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING